Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects.
作者信息
Ye Sisi, Li Juan, Xu Jianming
机构信息
Department of Oncology, Fifth Medical Center of the Chinese PLA General Hospital, Beijing 100071, China.
Department of Oncology, First Medical Center of the Chinese PLA General Hospital, Beijing 100853, China.
出版信息
Cancer Biol Med. 2025 Jan 3;22(1):14-20. doi: 10.20892/j.issn.2095-3941.2024.0507.
Abstract
摘要
相似文献
1
Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects.
Cancer Biol Med. 2025 Jan 3;22(1):14-20. doi: 10.20892/j.issn.2095-3941.2024.0507.
2
Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Int J Mol Sci. 2017 Jan 13;18(1):143. doi: 10.3390/ijms18010143.
3
A Review of the Evolving Role of Radiotherapy in the Treatment of Neuroendocrine Neoplasms.
Neuroendocrinology. 2024;114(9):856-865. doi: 10.1159/000538140. Epub 2024 Mar 2.
4
Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
Curr Drug Targets. 2020;21(4):389-405. doi: 10.2174/1389450119666191014105211.
5
Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) - Current literature review of diagnostics and therapy. What has changed in the management?
Pol Przegl Chir. 2024 Mar 8;96(4):58-66. doi: 10.5604/01.3001.0054.4169.
6
Neuroendocrine cervical carcinomas: genomic insights, controversies in treatment strategies, and future directions: a NeCTuR study.
Int J Gynecol Cancer. 2025 Mar;35(3):101639. doi: 10.1016/j.ijgc.2025.101639. Epub 2025 Jan 11.
7
What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?
Curr Oncol Rep. 2022 Apr;24(4):451-461. doi: 10.1007/s11912-022-01235-x. Epub 2022 Feb 16.
8
The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types.
Oncologist. 2019 Jan;24(1):54-61. doi: 10.1634/theoncologist.2018-0187. Epub 2018 Aug 13.
9
Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
Eur J Radiol. 2021 Oct;143:109932. doi: 10.1016/j.ejrad.2021.109932. Epub 2021 Aug 25.
10
Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
Eur J Cancer Care (Engl). 2021 Nov;30(6):e13504. doi: 10.1111/ecc.13504. Epub 2021 Aug 30.
本文引用的文献
1
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).
Nat Commun. 2024 Aug 8;15(1):6753. doi: 10.1038/s41467-024-50969-8.
2
[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.
3
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
Eur J Cancer. 2024 Mar;199:113539. doi: 10.1016/j.ejca.2024.113539. Epub 2024 Jan 15.
4
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Nat Commun. 2023 May 23;14(1):2973. doi: 10.1038/s41467-023-38611-5.
5
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.
Lancet Oncol. 2023 Mar;24(3):297-306. doi: 10.1016/S1470-2045(23)00001-3. Epub 2023 Feb 2.
6
S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial.
EClinicalMedicine. 2022 Sep 26;54:101667. doi: 10.1016/j.eclinm.2022.101667. eCollection 2022 Dec.
7
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
JAMA Oncol. 2022 Jun 1;8(6):904-909. doi: 10.1001/jamaoncol.2022.0212.
8
Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden.
Cancer Med. 2022 Jul;11(13):2588-2600. doi: 10.1002/cam4.4628. Epub 2022 Mar 14.
9
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
Eur J Cancer. 2021 Nov;157:403-414. doi: 10.1016/j.ejca.2021.06.056. Epub 2021 Sep 28.
10
Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors.
Neuroendocrinology. 2022;112(6):537-546. doi: 10.1159/000518650. Epub 2021 Jul 26.
Zotero 插件